MedTrace Logo

Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy Subjects

NCT05369078 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2022-05-11

No results posted yet for this study

Summary

The purpose of this study was to investigate Safety, tolerability and pharmacokinetics in Chinese healthy subjects.

Conditions

  • T2DM (Type 2 Diabetes Mellitus)

Interventions

DRUG

THR-1442 20mg Single dose

THR-1442 20mg is administrated 1 dose on Day 1, then follow till day 7.

DRUG

THR-1442 20mg Multiple dose group

THR-1442 20mg is administrated QD for 7days, then follow till day 14.

Sponsors & Collaborators

  • Newsoara Biopharma Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2022-05-31
Completion
2022-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05369078 on ClinicalTrials.gov